BIO supports American Research and Competitiveness Act.
Share:
Press Release Summary:
BIO applauds U.S. House passage of the American Research and Competitiveness Act (H.R. 4438), which would establish a permanent research tax credit. According to BIO President and CEO Jim Greenwood, the R&D tax credit is a vitally important incentive that spurs private-sector funding of the search for new cures and treatments for patients in need. This research not only produces new groundbreaking medical discoveries, but also supports millions of well-paying American jobs.
Original Press Release:
BIO Applauds House Passage of the American Research and Competitiveness Act
Bill would strengthen, make permanent critical R&D tax credit
WASHINGTON--The Biotechnology Industry Organization applauds the passage today by the US House of Representatives of the American Research and Competitiveness Act (H.R. 4438), which would establish a permanent research tax credit.
“The R&D tax credit is a vitally important incentive that spurs private-sector funding of the search for new cures and treatments for patients in need. This research not only produces new groundbreaking medical discoveries, but also supports millions of well-paying American jobs.”
The following statement may be attributed to BIO President and CEO Jim Greenwood:
“BIO strongly supports the American Research & Competitiveness Act (H.R. 4438), which would strengthen and make permanent the R&D tax credit, and we thank Rep. Kevin Brady (R-TX) for his leadership.”
“The R&D tax credit is a vitally important incentive that spurs private-sector funding of the search for new cures and treatments for patients in need. This research not only produces new groundbreaking medical discoveries, but also supports millions of well-paying American jobs.”
“The current environment of uncertainty about whether the credit will be extended makes tax planning extremely difficult for companies preparing their development programs. Making the credit permanent would recognize its vital role in supporting America’s innovation economy while providing certainty for businesses working toward the next generation of medical breakthroughs.”
“The R&D tax credit is an important tool incentivizing investment at companies with established revenue streams, and we welcome this bill to strengthen and make it permanent.”
“However, it is important to recognize the tremendous investments in research made by smaller, pre-revenue companies which do not yet have a tax liability. Such companies are unable to take advantage of the R&D tax credit as currently structured. BIO believes that this critical research should be incentivized in the tax code regardless of the size of the company involved, and we hope to work with Congress to that end.”
For more information on policies affecting emerging biotech companies, please visit http://www.bio.org/ecs.
About BIO
BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIOtechNOW is BIO's blog chronicling “innovations transforming our world” and the BIO Newsletter is the organization’s bi-weekly email newsletter. Subscribe to the BIO Newsletter.
Upcoming BIO Events
World Congress on Industrial Biotechnology
May 12-15, 2014
Philadelphia, PA
BIO International Convention
June 23-26, 2014
San Diego, CA
BIO Latin America Conference
September 9-11, 2014
Rio de Janeiro, Brazil
Livestock Biotech Summit
September 16-18, 2014
Sioux Falls, SD
Contacts
Biotechnology Industry Organization
Daniel Seaton, 202-470-5207
Web: www.bio.org
Blog: www.biotech-now.org
Twitter: @IAmBiotech
